Month: May 2023

COLMAR, Penn., May 15, 2023 (GLOBE NEWSWIRE) — Dorman Products, Inc. (NASDAQ:DORM) announced today the release of almost 200 new motor vehicle parts, more than a third of which are aftermarket-exclusive repair solutions. The new products provide repair professionals and owners greater freedom to fix motor vehicles and expand revenue and profit opportunities for Dorman’s retailers and distributors. This month’s new releases include a first-to-the-aftermarket suspension sway bar bracket kit (928-581) designed to fit more than one million 2011-2015 Jeep Grand Cherokee and Dodge Durango SUVs on the road today. When the sway bar bushings fail on those popular vehicles, the dealer solution is to offer a complete sway bar assembly. The new Dorman® OE FIX™ suspension sway bar bracket kit is designed to be installed on the factory...

Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at the European Hematology Association (EHA) Congress in June 2023; topline data from both BEACON and AURORA studies expected by end of 2023 Two separate, ongoing Phase 1b/2 studies of DISC-0974 in patients with anemia of chronic kidney disease who are not receiving dialysis (NDD-CKD) and also in patients with myelofibrosis and anemia; interim data expected by end of 2023 In-licensed anti-TMPRSS6 monoclonal antibodies from Mabwell Therapeutics; Phase 1 trial expected to start 2H 2023 Completed $62.5 million financing led by Bain Capital Life SciencesWATERTOWN, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...

ISS states WM Argyle’s campaign critique “amounts to a one-dimensional observation” and “fails to establish a cohesive argument” CICERO, Ill., May 15, 2023 (GLOBE NEWSWIRE) — Broadwind, Inc. (Nasdaq: BWEN) (“Broadwind” or the “Company”) today announced that leading proxy advisory firms, Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), have both recommended Broadwind stockholders vote on the Company’s WHITE proxy card in favor of all seven of Broadwind’s director nominees, as well as all other management proposals, at the upcoming 2023 annual meeting of stockholders scheduled to be held on May 23, 2023 (the “2023 Annual Meeting”). In its report, ISS1 notes the following:“BWEN has already booked its first win in this new environment, announcing the largest tower order in company history in...

Figure 1 Quarterly Production and AISC ChartFigure 2 Quarterly Total Ore Processed, Development Metres Advanced and Total Mined Material ChartFigure 3 Ore Processed Daily Records ChartVANCOUVER, British Columbia, May 15, 2023 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three months ended March 31, 2023. SafetyZero Lost Time Injuries (“LTI”) during the quarter, and proactive and focused management of COVID-19. K92 has continuously operated throughout the COVID-19 pandemic, and has strong preventative and response plans in place.ProductionRecord monthly ore processed achieved in March, averaging 1,490 tonnes per day (“tpd”), 9% above the Stage 2A Expansion run-rate of 1,370 tpd. Multiple new daily records set during the quarter,...

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into a stock purchase agreement (the “Stock Purchase Agreement”) with funds affiliated with EW Healthcare Partners (the “Investors”). Pursuant to the Stock Purchase Agreement, the Company may issue and sell to the Investors up to $9,000,000, before offering expenses, in shares of senior convertible preferred stock (the “Senior Preferred Stock”), in multiple tranches from time to time until December 31, 2025. Offering proceeds will be used for working capital and general corporate purposes. At the initial closing, expected to occur today, the Investors will purchase 280,899 Senor Preferred Stock at a price of $7.12 per share for total gross...

Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28 Daily subcutaneous injections of 25 mg CTI-1601 for 14 days led to increases in frataxin levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) Median placebo-adjusted increases from baseline of 3.5 pg/µg and 0.9 pg/µg in frataxin levels observed in skin and buccal cells, respectively, with 14 days of daily dosing of CTI-1601 Larimar has submitted data to FDA and will meet with the Agency to discuss next steps; update expected in Q3 2023 Company management to host webcast and conference call today at 8:00 a.m. ETBALA CYNWYD, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:...

Oxford Biomedica launches TetraVectaTM – the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral vectors, while incorporating new and enhanced safety features, adding to the Company’s client offering and its leading LentiVector® platform. The TetraVectaTM system significantly enhances the development and manufacture of safer and more effective lentiviral vector-based therapies. This enables cell and gene therapy companies to overcome previous barriers in therapeutic development,...

— Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 — — SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of this year — — Results from the Phase 2b SYMMETRY study, evaluating treatment of patients with compensated cirrhosis due to NASH, on track to be reported in the fourth quarter of this year – — After close of the first quarter, $124.2 million in net proceeds raised through Akero’s ATM Facility SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high...

Priority drill targets confirmed by 500-kilometer Airborne Mobile MT geophysical survey Coincident geochemical, geological and geophysical targets supported by multi-percent copper values recovered from select surface samples Maiden drill hole collared at Central Breccia Zone Target Construction of Sobek Central access road continues to the higher elevations to support future drilling at the VN-Zone gold-copper targetVANCOUVER, British Columbia, May 15, 2023 (GLOBE NEWSWIRE) —  Mirasol Resources Ltd. (TSX-V: MRZ) (OTC: MRZLF) (the “Company” or “Mirasol”) is pleased to report that drilling has commenced on the Company’s 100%-owned Sobek Copper Project (“Sobek”) in the Vicuña District, Chile. Sobek was originally staked based on prospective local structural architecture prior to the 2021 discovery of the high-grade feeder zone...